Androgen deprivation and thromboembolic events in men with prostate cancer

Cancer

Volumn 118, Issue 13, 2012, Pages 3397-3406

  Ehdaie, Behfar ^a   Atoria, Coral L ^a   Gupta, Amit ^a   Feifer, Andrew ^a   Lowrance, William T ^a   Morris, Michael J ^a   Scardino, Peter T ^a   Eastham, James A ^a   Elkin, Elena B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen deprivation; Arterial embolism; Deep vein thrombosis; Prostate cancer; Pulmonary embolism

Indexed keywords

GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTERY EMBOLISM; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORCHIECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PULMONARY EMBOLISM; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 84858027124     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26623     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523. (Pubitemid 36132976)
3. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005; 103: 1615-1624. (Pubitemid 40490022)
4. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR,. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003; 95: 981-989. (Pubitemid 36896715)
5. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22: 232-240.
6. Baba K, Yajima M, Carrier S, et al. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology. 2000; 56: 533-538. (Pubitemid 30658203)
7. Karling P, Hammar M, Varenhorst E,. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994; 152: 1170-1173. (Pubitemid 24283460)
8. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS,. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110: 1493-1500. (Pubitemid 47463063)
9. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4456. (Pubitemid 46630983)
10. Nelson CJ, Lee JS, Gamboa MC, Roth AJ,. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008; 113: 1097-1106.
11. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 2420-2425. (Pubitemid 46999213)
12. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010; 11: 450-458.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-IV-18.
14. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 1075-1079.
15. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267. (Pubitemid 32007842)
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370: 1453-1457.
17. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87: 599-603. (Pubitemid 34158224)
18. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91: 1305-1308.
19. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167: 2361-2367. (Pubitemid 34533125)
20. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102: 39-46.
21. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001; 86: 4261-4267. (Pubitemid 32848544)
22. Li S, Li X, Li J, Deng X, Li Y, Cong Y,. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res. 2007; 121: 127-134. (Pubitemid 350026003)
23. Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood. 2000; 95: 2289-2296. (Pubitemid 30167727)
24. Lippi G, Plebani M, Franchini M, Guidi GC, Favaloro EJ,. Prostate-specific antigen, prostate cancer, and disorders of hemostasis. Semin Thromb Hemost. 2009; 35: 654-664.
25. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A,. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003; 112: 853-862. (Pubitemid 38063743)
26. Rickles FR, Falanga A,. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001; 102: V215-V224. (Pubitemid 32539212)
27. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH,. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110: 2339-2346. (Pubitemid 350100757)
28. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd,. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160: 809-815. (Pubitemid 30165241)
29. Klevecka V, Burmester L, Musch M, Roggenbuck U, Kroepfl D,. Intraoperative and early postoperative complications of radical retropubic prostatectomy. Urol Int. 2007; 79: 217-225. (Pubitemid 47586929)
30. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591. (Pubitemid 351264352)
31. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295. (Pubitemid 351159365)
32. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827. (Pubitemid 39079668)
33. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850. (Pubitemid 41614795)
34. Nguyen PL, Chen MH, Beard CJ, et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010; 77: 1046-1052.
35. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003; 170: 791-794. (Pubitemid 36999557)
36. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002; 94: 430-437. (Pubitemid 34285092)
37. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
38. D'Amico AV, Denham JW, Bolla M, et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007; 109: 2004-2010. (Pubitemid 46744194)
39. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978. (Pubitemid 46606211)
40. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78: 285-291. (Pubitemid 29439263)
41. Brown BW, Brauner C, Minnotte MC,. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993; 85: 979-987. (Pubitemid 23177584)
42. Shahinian VB, Kuo YF, Gilbert SM,. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010; 363: 1822-1832.
43. Weight CJ, Klein EA, Jones JS,. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008; 112: 2195-2201. (Pubitemid 351628629)